# Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

> **NCT05093517** · EARLY_PHASE1 · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 4 (actual)

## Conditions studied

- Type 2 Diabetes
- Glucose Tolerance Impaired
- Insulin Sensitivity

## Interventions

- **DRUG:** REMD-477
- **DRUG:** Placebo Subcutaneous injection

## Key facts

- **NCT ID:** NCT05093517
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-10
- **Primary completion:** 2022-03-16
- **Final completion:** 2022-03-16
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05093517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05093517, "Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05093517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*